Uncategorized
Analysis: Lucentis and Eylea comparable in injection frequency, cost in AMD patients at 2 years
SEATTLE — Ranibizumab and aflibercept were shown to be comparable in injection frequency and cost for the treatment of patients with neovascular age-related macular degeneration at 2 years, according to a poster presented here. “In terms of the real-world use of aflibercept and ranibizumab, there seems to be no difference whether the patient is treatment naïve or treatment experienced, and that’s true at 1 year and at 2 years,” Szilárd Kiss, MD, told Ocular Surgery News in an interview at the Association for Research in Vision and Ophthalmology meeting.